Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

Standard of care

Standard of care

GIST treatment depends on genotype, resectability, recurrence risk, and prior therapy. Complete resection remains central for localized disease. The usual advanced sequence is imatinib, then sunitinib, then regorafenib, then ripretinib, with molecular exceptions. Bezuclastinib plus sunitinib remains investigational as of November 7, 2026. Its target FDA action date is November 30, 2026. Pending review is not approval.

NOT INVESTMENT ADVICE. This is a general evidence review, not individualized medical advice. A line is shown only when the cited review or a trial record in this file states it.

No drugs selected. The grid shows every stated option.

How to read a tile

  • Filled tile. Approved for that lane.
  • Outlined tile. Guideline or off label. Local, Exception, and Not established use the same outline with those words.
  • Dashed tile. Investigational, with the phase and any stated FDA date. Pending review is not approval.

An empty cell reads “No standard.” The words on the tile carry the status. Border style repeats it.

SubgroupLocalized, surgeryNeoadjuvantAdjuvantFirst lineSecond lineThird lineFourth line or later
KIT exon 11KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.
KIT exon 9The review states KIT exon 9 often uses imatinib 400 mg twice daily.
PDGFRA D842VThe review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.

No standard

No standard

No standard

No standard

No standard

Other PDGFRASensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.
SDH-deficient or NF1The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.

No standard

No standard

No standard

No standard

No standard

No standard

Rare NTRK fusion or BRAF V600EThe review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.

No standard

No standard

No standard

No standard

No standard

No standard

Localized, surgery

KIT exon 11

KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.

PDGFRA D842V

The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.

Other PDGFRA

Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.

SDH-deficient or NF1

The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.

Rare NTRK fusion or BRAF V600E

The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.

Neoadjuvant

KIT exon 11

KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.

KIT exon 9

The review states KIT exon 9 often uses imatinib 400 mg twice daily.

PDGFRA D842V

The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.

No standard

Other PDGFRA

Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.

SDH-deficient or NF1

The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.

No standard

Rare NTRK fusion or BRAF V600E

The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.

No standard

Adjuvant

KIT exon 11

KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.

KIT exon 9

The review states KIT exon 9 often uses imatinib 400 mg twice daily.

PDGFRA D842V

The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.

No standard

Other PDGFRA

Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.

SDH-deficient or NF1

The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.

No standard

Rare NTRK fusion or BRAF V600E

The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.

No standard

First line

PDGFRA D842V

The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.

Other PDGFRA

Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.

SDH-deficient or NF1

The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.

No standard

Rare NTRK fusion or BRAF V600E

The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.

No standard

Second line

PDGFRA D842V

The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.

No standard

SDH-deficient or NF1

The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.

No standard

Rare NTRK fusion or BRAF V600E

The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.

No standard

Third line

PDGFRA D842V

The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.

No standard

SDH-deficient or NF1

The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.

No standard

Rare NTRK fusion or BRAF V600E

The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.

No standard

Fourth line or later

KIT exon 11

KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.

PDGFRA D842V

The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.

No standard

SDH-deficient or NF1

The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.

No standard

Rare NTRK fusion or BRAF V600E

The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.

No standard

Line not stated

The cited review names these options and does not assign them to a numbered line.

Sources

  • G1GEIS guidelines for gastrointestinal stromal tumors, 2023Open multidisciplinary guideline. International evidence, not a U.S. regulatory label.
  • G2NCI gastrointestinal stromal tumors treatment PDQU.S. evidence summary.
  • G3NCCN Guidelines Insights, gastrointestinal stromal tumors, version 2.2022Public 2022 Insights article, not a verified current full NCCN version.
  • G4SSGXVIII/AIO ten year analysis of adjuvant imatinibJoensuu et al., JAMA Oncology 2020. Randomized three versus one year.
  • G5IMADGIST, six versus three years of adjuvant imatinibBlay et al., Annals of Oncology 2024. Randomized phase III.
  • G6MetaGIST comparison of two imatinib dosesJCO 2010. Mutation subgroup analysis.
  • G7Randomized sunitinib study after imatinib failureDemetri et al., Lancet 2006.
  • G8GRID randomized phase III regorafenib studyDemetri et al., Lancet 2013.
  • G9INVICTUS randomized phase III ripretinib studyBlay et al., Lancet Oncology 2020.
  • G10AYVAKIT U.S. prescribing informationAvapritinib indication, dose, and safety.
  • G11NAVIGATOR long term PDGFRA D842V cohortJones et al., European Journal of Cancer 2021. Phase I, single arm.
  • G12BFR14 interruption versus continuation of imatinibBlay et al., Lancet Oncology 2024.
  • G13QINLOCK U.S. prescribing informationRipretinib indication and safety.
  • G14PEAK phase III detailed results and regulatory updateCogent sponsor report from ASCO 2026. Investigational as of the review date.
  • G15FDA acceptance of the bezuclastinib GIST applicationSponsor announcement May 28, 2026. Target action date November 30, 2026.
  • G16GLEEVEC U.S. prescribing informationUpdated July 2026.
  • G17SUTENT U.S. prescribing informationGIST indication, labeled 4 weeks on and 2 weeks off schedule, dose modification, and safety.
  • G18STIVARGA U.S. prescribing informationUpdated February 2026.
  • X1NCI tissue agnostic cancer therapies PDQBiomarker specific eligibility and label restrictions apply.
  • NCT07218926StrateGIST 3, ClinicalTrials.govPrimary registry record cited for the velzatinib versus sunitinib phase 3 design.
  • ASCO-TPS11588StrateGIST 3 trial in progress abstract, ASCO 2026States the randomized design and the sunitinib 4 weeks on, 2 weeks off control.
  • NCT07585266StrateGIST Frontline, ClinicalTrials.govPrimary registry record cited for frontline velzatinib versus imatinib.
  • NCT07379047GISTAR-1, ClinicalTrials.govPrimary registry record cited for NB003 versus regorafenib in third line, and an uncontrolled second line arm.
  • ASCO-11517NB003 phase 1 abstract, ASCO 2025Reports third line and fourth line cohorts. Efficacy numbers are not copied into the seed.
  • NATURE-SDHOlverembatinib in SDH deficient GIST, phase 1bPeer reviewed report of the SDH deficient cohort. Response counts are not copied into the seed.
  • NCT06640361POLARIS-3, ClinicalTrials.govRegistry identifier cited beside the SDH deficient olverembatinib cohort. The record as cited does not state a separate line.
  • NCT05734105INSIGHT, ClinicalTrials.govPrimary registry record for ripretinib in ctDNA selected GIST after imatinib.
  • PUBMED-35947817INTRIGUE primary publicationBauer et al., JCO 2022. Overall comparison after imatinib did not show superiority. Exploratory plasma DNA signals are cited as the reason for INSIGHT.
  • VOYAGERVOYAGER, avapritinib versus regorafenibKang et al., JCO 2021. Cited in the GIST seed.
  • ASCO-11501StrateGIST 1 abstract, ASCO 2026Congress abstract already quoted in the GIST seed. Preliminary.
  • ESMO-NB003NB003 phase 1 report cited for GISTAR-1Quote already stored in the GIST seed.
  • ASCO-11539Olverembatinib in SDH deficient GIST, ASCO 2026 abstractCongress abstract already quoted in the GIST seed. Preliminary.

All drugs